A Phase 1-2 Study of Imexon Plus Dacarbazine in Patients With Unresectable Metastatic Melanoma.

The article discusses a study on the overall toxicities and the dose limiting toxicity (DLT) of a combined imexon and dacarbazine including its maximal tolerated dose (MTD) and antitumor efficacy. Pharmacokinetic studies of the two drugs were done in the phase 2 portion of the study in selected patients aged 18 years and above with inoperable stage 3 or 4 melanoma. The study concluded that the combination of imexon and dacarzabine was tolerated well by patients with metastatic melanoma but did not produce an increased progression-free survival.